NCT00972335View on ClinicalTrials.gov

Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma

PHASE2TerminatedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Intracranial Meningioma
Interventions
DRUG

Everolimus

This drug will be dosed at 10 mg orally DAILY for the duration of the study.

DRUG

Bevacizumab

This drug will be given IV at 10 mg/kg on Days 1 and 15 of each 28-day treatment cycle for the duration of the study.

Trial Locations (7)

15232

University of Pittsburgh Medical Center, Pittsburgh

23601

Peninsula Cancer Institute, Newport News

32804

Florida Hospital Cancer Insitute, Orlando

37023

Tennessee Oncology, PLLC, Nashville

38104

UT Cancer Insititute Memphis, Memphis

40207

Norton Cancer Institute, Louisville

68114

Nebraska Methodist Cancer Center, Omaha

Sponsors

Collaborators (2)

Genentech, Inc.
Novartis
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Novartis

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER

NCT00972335 - Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma | Biotech Hunter | Biotech Hunter